Corcept Therapeutics (CORT) Reports Q2 2025 Earnings Results
Corcept Therapeutics (CORT) reported Q2 2025 earnings with revenue of $194.4 million, up from $163.8 million, though net income slightly declined to $35.1 million. The company also announced revenue guidance for 2025 of $850 million to $900 million and highlighted challenges from pharmacy vendor delays impacting revenue by $15 million.
Tickers: $CORT
Topics: Authorized Generic Transition Drug Approval Timeline Earnings Net Income New Pharmacy Onboarding Pharmacy Fulfillment Revenue Growth Sales Force Expansion Share Repurchase